KMT2D and melanoma: To test this notion, we inoculated subcutaneously the wild-type and mutant B16 melanoma cells deleted for Mll3, Mll4, or both (DKO) into immune-competent syngeneic C57BL/6J mice or immune-compromised BALB/c nude mice and Rag1−/− mice.